Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.

To describe the efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) or ankylosing spondylitis (AS) in a post-hoc analysis of randomised controlled trials. Data were collected from patients in seven tofacitinib studies: six phase III (four RA, two PsA) and one phase II study (AS), and grouped into five analysis populations based on rheumatic disease diagnosis and category of prior inadequate response (IR) to treatment: conventional synthetic disease-modifying antirheumatic drugs-IR (RA and PsA), tumour necrosis factor inhibitors-IR (RA and PsA), or non-steroidal anti-inflammatory drugs-IR (AS). Only patients who received tofacitinib 5 or 10 mg twice daily or placebo were included. Pain assessments included: Patient's Assessment of Arthritis Pain, Short-Form Health Survey 36v2 Question (Q)7 and Bodily Pain domain, Ankylosing Spondylitis Quality of Life Q9 and Q14, EuroQol Five Dimensions Pain/Discomfort dimension and Bath Ankylosing Spondylitis Disease Activity Index Q2 and Q3. Data were reported to month 6 (placebo to month 3) in the RA and PsA populations, and week 12 (tofacitinib and placebo) in the AS population. Overall, 3330 patients were included in this analysis. In the RA and PsA populations, pain improvements in tofacitinib-treated patients compared with placebo were observed at the earliest time point assessed and at month 3 (maintained to month 6). In the AS population, pain improvements compared with placebo were observed at week 12. Tofacitinib was associated with rapid and sustained improvements across multiple pain measures in patients with inflammatory rheumatic musculoskeletal diseases.

Informations de copyright

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: AO has served as a consultant for AbbVie, Amgen, BMS, Celgene, Corrona, Eli Lilly, Novartis, Pfizer Inc and Takeda, and has received grant support from Novartis and Pfizer Inc. KdV has received consulting fees or other remuneration from Eli Lilly and Pfizer Inc, and has participated in a trial with Galapagos. IBM has received research grants from Celgene, Janssen, Novartis, Pfizer Inc, Roche and UCB, and has received consulting fees or other remuneration from AbbVie, Celgene, Janssen, Novartis and UCB. PJM has received research grants from AbbVie, Amgen, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer Inc, Sun Pharmaceutical and UCB, has received consulting fees or other remuneration from AbbVie, Amgen, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer Inc, Sun Pharmaceutical and UCB, and is on the speakers’ bureau for AbbVie, Amgen, BMS, Celgene, Genentech, Janssen, Novartis, Pfizer Inc and UCB. PB has received consulting fees or other remuneration from AbbVie, Amgen, Eli Lilly, Johnson and Johnson, Novartis, Paladin, Sanofi-Genzyme and Takeda, and is on the speakers’ bureau for Amgen, Eli Lilly, Janssen and Pfizer Inc. TL, DG, KK, CW, and M-AH are employees and shareholders of Pfizer Inc. AM is a shareholder, and was an employee, of Pfizer Inc during the time of this analysis.